Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**echinops cephalotes hexane fraction** is a plant-derived research extract obtained from *Echinops cephalotes* and studied in preclinical models of cognitive impairment. It is not a single purified active pharmaceutical ingredient but a **natural product mixture** prepared as a hexane-soluble fraction, and published data indicate **anti-acetylcholinesterase** and **anti-butyrylcholinesterase** activity together with reversal of **scopolamine-induced memory impairment** in mice in behavioral assays. The available evidence supports investigation as an early-stage experimental agent for neurodegenerative and memory-disorder indications, particularly **Alzheimer's disease**, but there is no clear evidence of commercial pharmaceutical development, approved use, or an established brand sponsor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echinops cephalotes hexane fraction.